Intellectual Property Due Diligence for Pre-IPO Companies: Patent and Trademark Compliance Checklist

The Hong Kong Stock Exchange (HKEX) dealt with 18 cases of material intellectual property (IP) deficiencies in listing applications during the 2024 review cycle, according to internal Exchange guidance issued in Q1 2025, representing a 50% increase from 12 cases in 2023. This spike coincides with the SFC’s heightened scrutiny under the Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (SFC Code, para 17.6), which now explicitly requires sponsors to verify that a pre-IPO company’s IP portfolio is “valid, enforceable, and owned by the listing applicant” as a condition for a viable listing proposition. For CFOs and pre-IPO investors structuring SPVs in the Cayman Islands or BVI, the margin for error has narrowed: a single unregistered patent assignment or a lapsed trademark registration in a key jurisdiction can trigger a HKEX return of the A1 application, delaying the listing timetable by 6-12 months and eroding valuation multiples by 200-400 bps in secondary market pricing. This article provides a compliance checklist grounded in HKEX Listing Rules, Chapter 9 (Equity Securities) and Chapter 18A (Biotech), alongside the SFC’s 2024 Guidance Note on Due Diligence for IP Assets, to map the exact procedural steps required for patent and trademark due diligence ahead of a Main Board filing.

The Regulatory Framework: HKEX and SFC Requirements for IP Assets

The HKEX Listing Rules impose a dual obligation on listing applicants regarding IP. Under HKEX Listing Rule 9.03(3), a prospectus must contain “all information necessary to enable a reasonable investor to make an informed assessment of the assets and liabilities of the group,” which directly encompasses IP assets. For companies seeking listing under Chapter 18A (Biotech), Rule 18A.03(2) further requires that the applicant “has a portfolio of patents, patent applications, and/or know-how that is material to its core product.” The SFC’s 2024 Guidance Note on Due Diligence for IP Assets (the “2024 GN”) operationalises these rules by mandating that sponsors verify the chain of title, validity, and freedom-to-operate for all material IP within 30 business days of the sponsor’s appointment.

Patent Verification: Chain of Title and Inventorship

The 2024 GN (para 4.2) requires sponsors to obtain a full patent assignment chain from each inventor to the company, executed in writing and recorded with the relevant patent office. For a pre-IPO company incorporated in the Cayman Islands with operating subsidiaries in the PRC, this means tracing assignments from PRC inventors to the Hong Kong or BVI holding company, then to the Cayman parent. A common deficiency identified in 2024 HKEX return letters was the absence of notarised assignments for patents filed in the China National Intellectual Property Administration (CNIPA) where the inventor remained the legal owner on record. The sponsor must confirm that all assignments are recorded within 3 months of execution under PRC Patent Law, Article 10, or risk the patent being deemed unenforceable against third parties.

Trademark Verification: Territorial Coverage and Use Evidence

Trademark due diligence under the HKEX framework focuses on territorial scope and actual use. HKEX Listing Rule 9.03(3) read with the 2024 GN (para 5.1) requires that all material trademarks—defined as marks used on products generating more than 5% of group revenue—be registered in each jurisdiction of manufacture and sale. For a pre-IPO company with a PRC manufacturing base and Hong Kong distribution, this means both CNIPA and HKIPD (Hong Kong Intellectual Property Department) registrations are mandatory. The sponsor must produce evidence of genuine use within the 3 years preceding the listing application, as failure to do so exposes the mark to non-use cancellation actions under the Trade Marks Ordinance (Cap. 559, s. 52). In 2024, HKEX queried 7 applicants on this point, resulting in 2 withdrawals where the applicant could not demonstrate use in Hong Kong.

The Due Diligence Process: A Procedural Checklist

The due diligence process for IP assets follows a structured four-phase approach that aligns with the HKEX’s Listing Decision LD43-3 (2023), which established the principle that IP due diligence must be “substantively complete” before the A1 submission. Each phase requires specific documentation and third-party verification, with the sponsor bearing primary liability under the SFC Code (para 17.6).

Phase 1: IP Asset Mapping and Materiality Assessment

The first phase involves creating a comprehensive register of all IP assets—patents, trademarks, designs, domain names, and trade secrets—owned, licensed, or used by the group. The materiality threshold, per the 2024 GN (para 3.1), is any IP asset that either (a) contributes to more than 10% of group revenue, (b) is essential for a core product’s regulatory approval, or (c) is subject to a litigation or opposition proceeding. For a biotech applicant under Chapter 18A, this includes all patents listed in the core product’s patent term extension application in the PRC, EU, and US. The sponsor must obtain a legal opinion from a qualified PRC patent attorney confirming the validity of each CNIPA patent, with a search of the CNIPA database conducted no more than 60 days before the A1 filing.

Phase 2: Chain of Title Verification

Phase 2 requires the sponsor to verify the chain of title for each material IP asset. This involves obtaining (a) executed assignment agreements from all named inventors, (b) employment agreements confirming the invention was made in the course of employment, and (c) recordation certificates from the relevant patent or trademark office. For a company with a BVI holding structure, the sponsor must also confirm that the IP has been properly contributed to the BVI entity under the BVI Business Companies Act (Cap. 50, s. 46), including a valuation report if the IP was contributed as non-cash consideration. A 2024 HKEX return letter cited a case where a PRC subsidiary had not recorded a patent assignment with CNIPA, rendering the BVI parent’s ownership claim unenforceable—the application was returned with a 6-month resubmission bar.

Phase 3: Freedom-to-Operate and Infringement Risk Assessment

The freedom-to-operate (FTO) analysis is the most resource-intensive phase and the one most frequently flagged by HKEX. Under HKEX Listing Rule 9.03(3) and the 2024 GN (para 6.1), the sponsor must commission an FTO search covering all jurisdictions where the company manufactures, sells, or intends to sell its products. For a pre-IPO company with a PRC manufacturing base and US distribution, this means searches of CNIPA, USPTO, and EPO databases for patents that could be infringed. The FTO report must identify each potentially blocking patent, assess its validity, and quantify the risk of infringement—defined as a “material risk” if the probability of a successful claim exceeds 20% under the HKEX Guidance Letter GL57-13 (para 4.2). If a blocking patent is identified, the sponsor must document a mitigation strategy, such as a license agreement or a design-around, with a legal opinion confirming the strategy’s viability.

Phase 4: IP Litigation and Opposition Disclosure

The final phase requires disclosure of all IP-related litigation, oppositions, or invalidation proceedings. Under HKEX Listing Rule 9.03(3) and Appendix 1, Part A, para 32, the prospectus must disclose any pending or threatened IP proceedings that could have a material adverse effect on the group. The materiality threshold, per the 2024 GN (para 7.2), is any proceeding where the amount in dispute exceeds 5% of the group’s net profit for the most recent financial year, or where the proceeding challenges the validity of a material patent. For a pre-IPO company, this includes PRC patent invalidation proceedings before the CNIPA Patent Reexamination Board, which are common in the pharmaceutical and technology sectors. In 2024, HKEX required 3 applicants to withdraw their A1 filings pending the outcome of such proceedings, as the Exchange considered the outcome “too uncertain” for a listing decision.

Common Deficiencies and Remediation Strategies

Analysis of HKEX return letters from 2023-2024 reveals three recurring deficiencies in IP due diligence that sponsors and CFOs must pre-empt. Each deficiency has a defined remediation pathway that, if executed within the HKEX’s prescribed timeline, can avoid a listing delay.

Deficiency 1: Incomplete Patent Assignment Chains

The most common deficiency, appearing in 14 of the 18 return letters in 2024, was an incomplete chain of title for material patents. The typical pattern involved a PRC subsidiary that had not recorded a patent assignment from an inventor with CNIPA, leaving the inventor as the legal owner on record. The remediation requires (a) executing a new assignment agreement retroactively, (b) obtaining a notarised statement from the inventor confirming the invention was made in the course of employment, and (c) filing the assignment with CNIPA, which takes 3-5 months for processing. The sponsor must then obtain a legal opinion confirming that the assignment is effective as of the original filing date under PRC Patent Law, Article 10, and that no third-party rights have intervened.

Deficiency 2: Lapsed Trademark Registrations in Key Jurisdictions

Seven return letters in 2024 cited lapsed trademark registrations in jurisdictions where the company generated more than 5% of revenue. The most common scenario was a PRC company that had registered its trademark with CNIPA but failed to renew it in Hong Kong, where it distributed products through a local distributor. The remediation requires (a) filing a new trademark application with HKIPD, which takes 6-9 months for registration, (b) obtaining a temporary license agreement from the distributor if the mark was used under a verbal arrangement, and (c) disclosing the lapsed registration and the remediation plan in the prospectus. The sponsor must also assess the risk of a third-party having filed a similar mark in the interim, which could block the new application under the Trade Marks Ordinance (Cap. 559, s. 12).

Deficiency 3: Inadequate Freedom-to-Operate Analysis for Core Products

Five return letters in 2024 cited an FTO analysis that did not cover all jurisdictions where the core product was manufactured or sold. The typical deficiency was a biotech company that only searched CNIPA and USPTO patents but ignored EPO patents, despite having a European distribution agreement. The remediation requires (a) commissioning a supplemental FTO search covering the omitted jurisdictions, (b) obtaining a legal opinion on the validity of any newly identified blocking patents, and (c) updating the prospectus risk factors to disclose the FTO risks. The sponsor must also confirm that the FTO search was conducted by a qualified patent attorney in each jurisdiction, as HKEX requires that the opinion be “from a person with relevant expertise” under the 2024 GN (para 6.3).

Actionable Takeaways for CFOs and Pre-IPO Investors

1. Begin the IP due diligence process no later than 12 months before the planned A1 submission, as patent assignment recordal with CNIPA takes 3-5 months and trademark registration in Hong Kong takes 6-9 months.
2. Commission a full patent chain-of-title audit from a qualified PRC patent attorney at least 9 months before filing, ensuring all inventor assignments are notarised and recorded with CNIPA under PRC Patent Law, Article 10.
3. Verify that all material trademarks are registered in each jurisdiction of manufacture and sale, with evidence of genuine use within the 3 years preceding the application, to avoid non-use cancellation risks under the Trade Marks Ordinance (Cap. 559, s. 52).
4. Engage a specialist IP law firm to conduct a freedom-to-operate search covering all jurisdictions where the core product is manufactured, sold, or intended to be sold, with the search completed no more than 60 days before the A1 filing.
5. Disclose all pending IP litigation, oppositions, or invalidation proceedings in the prospectus, with a quantified assessment of the financial and operational impact, as HKEX will require withdrawal if the outcome is deemed too uncertain under HKEX Guidance Letter GL57-13.